Keywords
survey
management guidelines
Paraguay
How to Cite
Abstract
Introducción: ANCA associated vasculitis are rare ,but can have devastating consequences if not diagnosed and treated in a timely manner. Diagnosis can be difficult and management generally requires a multidisciplinary team. EULAR managemente guidelines were published del 2016 , and outlines a series of reccomedations. The objective of this survey was to describe ANCA vascultis management by nefrologists and rheumatologists in Paraguay and compare them to current guidelines.
Methods: 10 question survey generated through Survey Monkey, based on key points/reccomendations outlined in the EULAR- ERA/EDTA guidelines. The surey was sent to adult rheumatologist and nephrologists registered with the Paraguayan Rheumatology Societies and the Paraguayan Nephrology Society. Answers were exported to Excel and analyzed with SPS.
Results: We had a 62 % participation rate. Most professionals (75%) obtain diagnostic biopsies. Renal biopsies were the most frequently obtained. Cyclophosphamide and Glucocorticoids were the most frequently used indcution treatment, and maintanance treatment varied according to specialty. Eighty percent of responants mantain treatment for at least 24 months.
Conclusion: ANCA associated vasculitis management by rheumatologist and nephrologist in Paraguay is in accordance to recommendations madeEULAR- ERA/EDTA management guidelines in 2016. Further studies are needed to determine reason for some of the differences encountered.
References
(1) Pierini FS, Scolnik M, Scaglioni v, Mollerach F, Soriano ER. incidence and prevalence of granulomatosis with polyangiitis and microscopic polyangiitis in health management organization in Argentina: a 15-year study. Clin Rheu- matol. 2019;38(7):1935-1940.
(2) Khan I, Watts RA. Classification of ANCA-associated vasculitis. Curr Rheu-
matol Rep. 2013;15(12):383.
(3) Hogan SL, Falk RJ, Chin H, Cai J, Jennette C, Jennete JC et al. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody- associated small-vessel vasculitis. Ann intern Med. 2005;13(9):621–631.
(4) Pagnoux C, Hogan SL, Chin H, et al. Predictors of treatment resis- tance and relapse in antineutrophil cytoplasmic antibody-associa- ted small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum. 2008;58:2908-2918.
(5) Tarzi RM, Pusey CD. Current and future prospects in the management of granulomatosis with polyangiitis (Wegener‘s granulomatosis). Ther Clin Risk Manag. 2014;10:279–293.
(6) Hiemstra TF, Walsh M, Mahr A, Savage C, Groot C, Harper L et al. Myco- phenolate mofetil vs azathioprine for remission maintenance in antineu- trophil cytoplasmic antibody-associated vasculitis: a randomized controlled trial. JAMA. 2010;304:2381-2388.
(7) Pagnoux C, Mahr A, Hamidou MA, et al. Azathioprine or methotrexate main- tenance for ANCA-associated vasculitis. N Engl J Med. 2008;359(26):2790- 2803.
(8) Yates M, Watts R, Bajema i, Cid M, Crestani B, Hauser T et al. validation of the EuLAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts. RMD Open. 2017;3(1):e000449.
(9) Vazquez v, Fayad A, González G, Smuclir Quevedo A, Robaina Sindín J; Consejo de Glomerulopatías de la Asociación Nefrológica de Buenos Aires, Sociedad Argentina de Nefrología. vasculitis asociada a ANCA con compromiso renal: guía de práctica clínica [Clinical practice guideline for ANCA-associated vasculitis with renal involvement]. Medicina (B Aires). 2015;75 Suppl 1:1–38.
(10) Aguirre v, Alvo M, Ardiles L, et al. Compromiso renal en vasculitis asociadas a anticuerpos anticitoplasma de neutrófilos. Recomendaciones de con- senso de las Sociedades Chilenas de Nefrología y Reumatología [Renal involvement in antineutrophil cytoplasmic antibodies (ANCA) associated vasculitides. Recommendations of the Chilean Societies of Nephrology and Rheumatology]. Rev Med Chil. 2018;146(2):241–248.
(11) Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74(6):1178–1182.
(12) Jayne DR, Gaskin G, Rasmussen N, et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol. 2007;18(7):2180-2188.
(13) Walsh M, Merkel PA, Jayne D. The Effects of Plasma Exchange and Reduced-Dose Glucocorticoids during Remission-induction for Treat- ment of Severe ANCAAssociated vasculitis [abstract]. Arthritis Rheumatol. 2018;70 (suppl 10).